Novo Nordisk, once the undisputed leader in the weight loss drug market with Ozempic and Wegovy, is now facing intense competition from Eli Lilly’s Zepbound, which has surpassed it in both efficacy and market share. CEO Maziar Doustdar acknowledges the company’s early missteps in understa
Sign up to read the full summary
Free AI-powered recaps of every episode, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.
Guest
Maziar Doustdar
interview on The Journal.
Mentions
Books, people, and resources mentioned in this episode.
People
Companies
Products & Tools
Topics
Listen to This Episode
More from The Journal.
Weight-Loss Drugs Are Gobbling Up Small Town Budgets
The Flu Shot Drama at the FDA
The Vape Cloud Hanging Over the FDA
Can't Get an IMAX Ticket? That's Kind of the Point.
The Great IPO Frenzy of 2026
For Riz Ahmed, Life is a Spy Thriller
Related episodes
From other shows on similar topics.
Ozempic for All?
The Daily
People are running their own experiments with GLP-1s — with stunning results
Apple News Today
What we got wrong about GLP-1s
Search Engine
Reshaping the GLP-1 Economy: A Breaking Consumer Study
We Fixed It, You're Welcome
Skinny and sad on GLP-1s
Today, Explained
Phil Vella: Ozempic: Life-Saving Drug or Dangerous Shortcut? | DSH #1820
Digital Social Hour
Get summaries like this every morning.
Free AI-powered recaps of The Journal. and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.